Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  NATIONAL STOCK EXCHANGE OF INDIA  >  Lupin    LUPIN   INE326A01037

My previous session
Most popular
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Lupin : appoints Dr. Kamal K. Sharma as Advisor to the Company

share with twitter share with LinkedIn share with facebook
share via e-mail
09/19/2018 | 03:32pm CEST

Mumbai - Lupin Limited announced today the appointment of Dr. Kamal K. Sharma as Advisor to the company, for a period of one year effective October 1, 2018.

During this period, Dr. Sharma will continue to hold the position of Vice Chairman of the Board in a Non-Executive capacity. Dr. Sharma has vast industry experience spanning over four decades and has held a range of senior management positions in the fields of projects, operations, corporate development and general management in the pharmaceutical and chemical industry.

Commenting on the appointment, Ms. Vinita Gupta, Chief Executive Officer and Mr. Nilesh Gupta, Managing Directorstated, 'Dr. Sharma has served Lupin for over 30 years and has helped drive the company to be a formidable pharmaceutical player globally. His decades of experience in the global pharmaceutical industry and commitment to our success has proved invaluable to the company. Dr. Sharma has always embodied the values that we believe in at Lupin. We look forward to his continued guidance on our strategic choices as we accelerate our efforts to evolve and grow our business.'

Speaking on the matter, Dr. Kamal K. Sharma, Vice-Chairman, said, 'I am honored by the confidence placed in me by the board, and look forward to the opportunity to guide Lupin through the dynamic changes in the global pharmaceutical industry.'

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 8th largest generics pharmaceutical company both in terms of market capitalization (30th June 2018, Bloomberg) and revenues (31st March 2018, Bloomberg LTM) globally. The Company is the 4th largest pharmaceutical player in the US by prescriptions (IQVIA MAT June 2018); 3rd largest Indian pharmaceutical company by global revenues (31st March 2018, Bloomberg LTM); 6 th largest generic pharmaceutical player in Japan and 5th largest company in the Indian Pharmaceutical Market (IQVIA MAT June 2018).

For the financial year ended 31st March, 2018, Lupin's Consolidated sales and Net profits before exceptional items were at Rs. 155,598 million (USD 2.41 billion) and Rs. 13,934 million (USD 216 million) respectively.

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rdFloor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.


Pooja Thakran

Tel: +91-22-66402531

Email: poojathakran@lupin.com

(C) 2018 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on LUPIN
09/19LUPIN : appoints Dr. Kamal K. Sharma as Advisor to the Company
09/18LUPIN : appoints Dr. Kamal K. Sharma as Advisor to the Company
09/18LUPIN : s Kamal K Sharma moves to non-executive role
09/15LUPIN : Usfda completes inspection of lupin unit
09/14LUPIN : receives FDA approval for generic Atovaquone Oral Solution USP
09/13LUPIN : Usfda nod to lupin's atovaquone suspension
09/12Gottlieb rebukes Nostrum's 300% price hike for generic antibiotic
09/07LUPIN : To train over 1k grads for pharma sector by 2020
09/06PATENT APPLICATION TITLED "STABLE PH : fc Fusion Protein" Published Online (USPT..
09/06LUPIN : Patent Issued for Stable Pharmaceutical Composition Of Etanercept In A P..
More news
Financials (INR)
Sales 2019 166 B
EBIT 2019 19 027 M
Net income 2019 13 467 M
Debt 2019 46 431 M
Yield 2019 0,72%
P/E ratio 2019 30,07
P/E ratio 2020 22,53
EV / Sales 2019 2,71x
EV / Sales 2020 2,37x
Capitalization 403 B
Duration : Period :
Lupin Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LUPIN
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 39
Average target price 800  INR
Spread / Average Target -10%
EPS Revisions
Nilesh Deshbandhu Gupta Managing Director & Executive Director
Vinita D. Gupta Chief Executive Officer & Executive Director
Manju Deshbandhu Gupta Chairman
Ramesh Swaminathan Chief Financial Officer & Executive Director
Alok Ghosh President-Technical Operations
Sector and Competitors
1st jan.Capitalization (M$)
LUPIN0.94%5 577
JOHNSON & JOHNSON2.26%383 312
PFIZER21.65%258 285
NOVARTIS-0.63%216 108
ROCHE HOLDING LTD.-4.60%211 501
MERCK AND COMPANY26.36%189 092